A pilot clinical and pharmacological study of intra-arterial infusion of thiotepa.
Fourteen patients with progressive localized tumors were treated on a clinical and pharmacological study with intra-arterial Thiotepa. A transfemoral percutaneous catheter was inserted into the major artery supplying the tumor. A venous catheter was inserted into the vein draining the tumor area for blood sampling. Doses of Thiotepa ranged from 0.3 mg/kg to 1.0 mg/kg. Courses were repeated monthly and doses of drug escalated as tolerated. Toxicity was mild and doses of drug at least up to 0.9-1.0 mg/kg were tolerable. Pharmacokinetic parameters suggest increasing binding of Thiotepa to tissue when the drug is administered by the intra-arterial route. Clinical responses were observed in a patient with melanoma and in another patient with unknown primary cancer.
Savaraj
N
N
Department of Oncology, Sylvester Comprehensive Cancer Center, University of Miami, FL 33136.
Feun
L G
LG
Blyden
G
G
Yrizarry
J M
JM
Hsiang
J T
JT
Curtas
J
J
Waldman
S
S
Post
J D
JD
Benedetto
P
P
Landy
H
H
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007261:Infusions, Intra-Arterial; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D010865:Pilot Projects; D013852:Thiotepa / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
D013852:Thiotepa